Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2023-08-11 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2023-08-11 English
Regulatory Filings 2023
Regulatory Filings
2023-08-10 English
SC TO-C Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing under Rule 14d-100 related to a tender offer by Symphony Acquisition Sub, Inc. and Regeneron Pharmaceuticals, Inc. to acquire Decibel Therapeutics, Inc. It includes detailed information about the tender offer, forward-looking statements, and references to related filings such as Schedule 14D-9 and proxy statements. The document is a formal regulatory filing specifically concerning a tender offer transaction, which is a type of merger and acquisition activity. The presence of terms like 'Tender Offer Statement', 'Schedule TO', and detailed transaction description confirms this is related to M&A activity. Therefore, the appropriate classification is Merger & Acquisition (MA).
2023-08-09 English
PRIMARY DOCUMENT
Director's Dealing
2023-08-03 English
PRIMARY DOCUMENT
Director's Dealing
2023-08-03 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.